SLC5A2 and chronic kidney disease: These studies, such as DAPA-CKD,32 which is testing the SGLT2 inhibitor dapagliflozin, include patients with IgAN; however, the requirement for maximizing RAASi tends to be less stringent (e.g., requirement for stable dose for at least 4 weeks, not specifically stating a requirement for an optimized dose or an MLD, and only if ACEi and/or ARB are not medically contraindicated27), and lower proteinuria thresholds equivalent to <1 g/d are applied.